{"id":28384,"date":"2024-05-14T14:52:32","date_gmt":"2024-05-14T19:52:32","guid":{"rendered":"https:\/\/myeloma.ca\/?p=28384"},"modified":"2024-05-15T09:21:32","modified_gmt":"2024-05-15T14:21:32","slug":"here-comes-the-may-flower-tecvayli-was-recommended-for-reimbursement-by-the-cda-amc","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/05\/14\/here-comes-the-may-flower-tecvayli-was-recommended-for-reimbursement-by-the-cda-amc\/","title":{"rendered":"L\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC) recommande le remboursement de Tecvayli!\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Nous sommes ravis d\u2019annoncer que le 24 avril dernier, le\u00a0<a href=\"https:\/\/www.cadth.ca\/pcodr-expert-review-committee-perc\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Comit\u00e9 d\u2019experts en examen du Programme pancanadien d\u2019\u00e9valuation des anticanc\u00e9reux<\/strong><\/a>\u202f(CEEP) de l\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC)* a recommand\u00e9 le remboursement de TECVAYLI (teclistamab) \u2013 le premier anticorps bisp\u00e9cifique pour lequel un remboursement est recommand\u00e9 au Canada.\u00a0\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La\u00a0<a href=\"https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2024\/PC0332%20Tecvayli%20-%20Final%20CADTH%20Rec.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">d\u00e9cision<\/a>\u00a0officielle du CEEP pr\u00e9voit que, sous r\u00e9serve d\u2019une r\u00e9duction du prix, teclistamab devrait \u00eatre rembours\u00e9 pour les adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui\u202font re\u00e7u au moins trois traitements ant\u00e9rieurs, dont un inhibiteur du prot\u00e9asome (IP), un agent immunomodulateur (IMiD), un anticorps monoclonal anti-CD38, et qui satisfont aux conditions additionnelles \u00e9num\u00e9r\u00e9es dans le rapport (page 5).\u202f\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Toutefois, cette recommandation ne permettra pas imm\u00e9diatement aux Canadiens d\u2019acc\u00e9der au remboursement de TECVAYLI. Des n\u00e9gociations de prix doivent d\u2019abord avoir lieu.\u202fN\u00e9anmoins, cela demeure une importante \u00e9tape vers l\u2019am\u00e9lioration de l\u2019acc\u00e8s aux nouveaux traitements pour le my\u00e9lome au Canada.\u00a0\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">*Le 1 mai, l\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 (ACMTS) est devenue l\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC). Les recommandations de l\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC) ne s\u2019appliquent pas au Qu\u00e9bec.&nbsp;&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nous sommes ravis d\u2019annoncer que le 24 avril dernier, le\u00a0Comit\u00e9 d\u2019experts en examen du Programme pancanadien d\u2019\u00e9valuation des anticanc\u00e9reux\u202f(CEEP) de l\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC)* a recommand\u00e9 le remboursement de TECVAYLI (teclistamab) \u2013 le premier anticorps bisp\u00e9cifique pour lequel un remboursement est recommand\u00e9 au Canada.\u00a0\u00a0 La\u00a0d\u00e9cision\u00a0officielle du CEEP pr\u00e9voit que, sous r\u00e9serve d\u2019une r\u00e9duction [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,53],"tags":[],"class_list":["post-28384","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=28384"}],"version-history":[{"count":2,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28384\/revisions"}],"predecessor-version":[{"id":28415,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/28384\/revisions\/28415"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=28384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=28384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=28384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}